Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats

Ravi Prakash Rao*, Ansima Singhb, Arun K Jainc, Bhartu Parsharthi Srinivasana

aDepartment of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi 110017, India;
bDepartment of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 201301, India;
cInstitute of Pathology, Indian Council of Medical Research (ICMR), New Delhi 110029, India.

Received 15 June 2011, Revised 15 August 2011, Accepted 08 September 2011

Abstract

Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) in the general population. It is estimated that diabetic nephropathy will eventually develop in about 40% of all patients with diabetes; therefore, prevention is critical for delaying the development and progression of diabetic kidney disease. Despite extensive efforts, medical advances are still not successful enough to prevent the progression of the disease. In the present study, we focused on the comparison of combination therapies and whether they offered additional renoprotection. Type 2 diabetes mellitus was induced by intraperitoneally administering streptozotocin (90 mg/kg) in neonatal rats and then these rats were treated with rosiglitazone (1.0 mg/kg) in combination with glimepiride (0.5 mg/kg) or with pioglitazone (2.5 mg/kg) in combination with glimepiride (0.5 mg/kg). Diabetic nephropathy markers were evaluated by biochemical and ELISA kits and renal structural changes were examined by light microscopy and transmission electron microscopy. Results show that the combination of pioglitazone with glimepiride is more effective in amelioration of diabetic nephropathy than rosiglitazone with glimepiride drug therapy due to glycemic control, suppressing albumin excretion rate, total protein excretion rate and augmented TNF-α signaling during the development of streptozotocin induced type 2 diabetic nephropathy.

Keywords: type 2 diabetes mellitus, diabetic nephropathy, peroxisome proliferator activated receptors (PPARs), transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α)

INTRODUCTION

Diabetes is a metabolic disorder characterized by chronically elevated blood glucose level above the normal range. Two main forms of diabetes are type 1 and type 2. Type 1 is an autoimmune disorder with complete loss of β-cell function. Type 1 diabetes is insulin dependent, the so called insulin dependent diabetes mellitus (IDDM). Type 2 diabetes, also known as non-insulin dependent diabetes mellitus (NIDDM), is more prevalent and responsible for 90% of the disease[1]. Type 2 diabetes is characterized by two basic abnormalities: impairment of insulin secretion and decrease in insulin action. Chronic hyperglycemia is a major initiator of diabetic micro- and macrovascular complications. Diabetic vascular complications are the leading cause of end stage renal failure, acquired blindness, and a variety of neuropathies and cardiovascular diseases, which account for disabilities and high mortality rates in patients with diabetes. Diabetic nephropathy is one of the main complications of dia-
betes, developing in 25%-40% of diabetic patients and finally leading to kidney transplantation and artificial dialysis treatment within 20-25 y \(^{1,2,3,4,5,6}\). Results of large scale epidemiological studies such as the UK Prospective Diabetes Study and Diabetes Control and Complications Trial indicated that hyperglycemia is the main cause of diabetic complications, including diabetic nephropathy \(^{7,8}\).

Glucose dependent pathways are activated within the diabetic kidney. These include increased oxidative stress, renal polyp formation, accumulation of advanced glycated end-products and secretion of pre-sclerotic cytokines, such as transforming growth factor-\(\beta 1\) (TGF-\(\beta 1\)). These pathways ultimately lead to increase in renal albumin permeability and extra cellular matrix accumulation, which results in increasing proteinuria, glomerulosclerosis and tubulointerstitial fibrosis \(^{9}\). Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) in the general population. It is estimated that DN will develop in about 40% of all patients with diabetes; therefore, prevention is critical for delaying the development and progression of diabetic kidney disease \(^{10,11,12}\). Once overt DN is present, ESRD can be postponed, but usually not prevented, even by effective antihypertensive treatment and careful glycaemic control \(^{13,14}\). Both peroxisome proliferator activated receptor \(\alpha/\gamma\) (PPAR \(\alpha/\gamma\)) are expressed in the kidney, and their agonists exhibit renoprotective effects in type 2 diabetes \(^{15}\). Thiazolidinediones (TZDs), the most widely used PPAR-\(\gamma\) agonists clinically, have become blockbuster drugs in the management of type 2 diabetes mellitus \(^{16}\). The UK Prospective Diabetes Study found that intensive treatment with sulfonylurea or insulin reduced microvascular complications by 15% \(^{7}\). Other investigators found that in inadequately controlled type 2 diabetic patients, the combination of sulfonylurea and TZD produces significant improvement in glycemic control and is safe and well tolerated \(^{17}\).

Researchers focus current therapeutic interventions on prevention or slowing of the progression of DN in experimentally induced type 2 diabetes using a combination of second generation sulfonylurea agent (glimepiride) and TZDs (pioglitazone and rosiglitazone). In the present study, we assessed the effect of combination therapy on the progression of DN by determining albumin excretion rate \(^{18}\), total protein excretion rate \(^{19}\), and contents of TGF-\(\beta 1\) \(^{20}\), fibronectin \(^{21}\), tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) \(^{22}\), and transferrin \(^{23}\) and by further studying renal structural changes.

### MATERIALS AND METHODS

**Animals**

The experimental protocol was approved by the Institutional Animal Ethical Committee (Protocol number: DIPSAR/IAEC/2007/12). Wistar albino rats of either sex weighing 150-250 g were procured from the animal house, DIPSAR, New Delhi, India. The animals were housed under standard laboratory conditions of \((21 \pm 2)^\circ\)C and a relative humidity of 55% and a 12:12 h light: dark cycle were maintained during the study. The animals were given standard rat pellet and tap water \(ad\ libitum\). Three female rats were caged with one male rat for mating. On the early morning of the next day, vaginal smears were checked for pregnancy. Smears showing the presence of sperms were identified as pregnant. The pregnant female rats were caged singly. After 21-23 d (gestation period), the animals that delivered pups (neonatal rats) were used for further studies.

**Induction of type 2 diabetes**

Streptozotocin (Sigma-Aldrich, St. Louis, MO, USA) at a dose of 90 mg/kg, in freshly prepared citrus buffer (0.1 mol/L, pH 4.5), was injected intraperitoneally to 2-d-old neonatal rats using 26 gauge needles \(^{24}\). The injection site was the dorsal midpoint between the pelvis and ribs close to the right side of the spine. Six w after the injection of streptozotocin (STZ), blood glucose of the induced rats was estimated. Animals showing fasting blood glucose \(\geq 150\) mg/dL were considered as type 2 diabetes mellitus positive rats \(^{25}\).

**Experimental groups**

Rats of either sex were randomly allotted into different experimental groups for 8 w (\(n = 7\) for each group). The first group was the normal control group treated orally with 0.5% carboxyl methyl cellulose (vehicle)(w/v). The second group was the diabetic control group treated orally with 0.5% carboxyl methyl cellulose (vehicle)(w/v). The third group was the diabetic group treated orally with a combination of rosiglitazone (1.0 mg/kg) and glimepiride (0.5 mg/kg). The fourth group was the diabetic group treated orally with a combination of pioglitazone (2.5 mg/kg) and glimepiride (0.5 mg/kg). The solutions of drugs were freshly prepared in 0.5% carboxyl methyl cellulose (w/v) before oral administration by an oral catheter on each morning.

**Collection of blood sample**

At the end of drug treatment, all the animals were fasted overnight but allowed free access to water. On the next morning, blood sample was withdrawn by the retro orbital sinus under mild ether anesthesia. The
blood samples were collected into a vacutainer, which had been precoated with EDTA as anticoagulant. Blood samples were centrifuged at 3,000 rpm for 10 min in a refrigerated centrifuge. The plasma separated as straw colored supernatant was used for various biochemical parameters. It was stored at -20°C until the completion of analysis.

Collection of urine sample
At the end of drug treatment, all the animals were kept in metabolic cages for 24 h. Animals were fasted but allowed free access to water. Urine samples were collected after 24 h in urine collecting bottles.

Measurement of renal function and biochemical parameters
Blood glucose was measured by Accu-Chek Active glucose strips. Albumin excretion rate and total protein excretion rate in urine were measured using Span and Ranbaxy diagnostic kits by autoanalyser (Echo, Logotech Pvt. Ltd, India). Plasma TGF-β1 (Diaclone, France), insulin (SPL Bio, USA), fibronectin (Assay-Pro, USA), TNF-α (Diaclone, France) and transferrin (ICL, USA) were measured by ELISA according to the instructions of the manufacturers.

Histopathological examination
At the end of the experiments, all rats were sacrificed and pathological analysis of the kidney was performed. The kidney tissues were preserved in buffered neutral formalin and stored at -20°C until being processed for histopathological studies[26]. Tissues were preserved in 1% (w/v) glutaraldehyde and 4% (w/v) formaldehyde in phosphate buffer (pH 7.2) at 4°C until being processed for electron microscopy. Tissues were processed for histopathological studies at room temperature. After processing, sections were stained using hematoxylin–eosin (H&E) stain using Harris’s alum hematoxylin and stock 1% (w/v) alcohol eosin solution. The stained sections were finally mounted in D.P.X. mountant. Light microscopy (× 400) was used for blinded qualitative histological analysis. Transmission electron microscopies of kidney samples of different groups were performed at the Institute of Pathology-ICMR, New Delhi, India.

Statistical analysis
The results were shown as mean±SEM. To analyze differences in variables before and after treatment, paired Student’s t-test was used. Comparison between different groups was done using one-way ANOVA followed by Student-Newman-Keuls Method. P values < 0.05 were considered statistically significant. Statistical analysis was done using Sigma Stat 3.5.

RESULTS
Fasting blood glucose
Blood glucose level was significantly increased in the diabetic group as compared to the control group (Table 1). Diabetic animals treated with the combination therapy of rosiglitazone with glimepiride and pioglitazone with glimepiride showed significant decrease in fasting blood glucose levels as compared with those before the drug treatment.

| Table 1 Changes in fasting blood glucose in studied groups (mean ± SEM, n = 6) |
|-----------------------------|-----------------------------|-----------------------------|
|                             | Fasting blood glucose (mg/dL) | Fasting blood glucose (mg/dL) |
|                             | Before treatment              | After treatment              |
| N                           | 80.0±2.5                      | 102.0±2.5                    |
| D                           | 192.0±2.5                     | 171.0±2.5                    |
| P + G                       | 183.0±7.0                     | 100.0±5.5^                 |
| R + G                       | 169.0±8.0                     | 108.0±4.4^                  |

N: Normal control; D: Diabetic control; P+G: Pioglitazone + Glimepiride; R+G: Rosiglitazone + Glimepiride. ^ P < 0.01 compared with before treatment.

Albumin excretion rate in urine
Albumin excretion rate was significantly increased in the diabetic group as compared to the normal control group (Table 2). There was a significant decrease in albumin excretion rate in the treated group compared to the diabetic group. Additionally, more significant decrease was found in the pioglitazone and glimepiride combination group compared with the rosiglitazone and glimepiride combination group.

Total protein excretion rate in urine
Total protein excretion rate was significantly increased in diabetic group as compared to normal control group (Table 2). There was a significant decrease in total protein excretion rate in the treated group compared to the diabetic group. Additionally, more significant decrease was found in the pioglitazone and glimepiride combination treatment group compared with the rosiglitazone and glimepiride combination treatment group.

Plasma fibronectin
Plasma fibronectin was significantly increased in the diabetic group as compared to the normal con-
There was a significant decrease in plasma transferrin in the treated group compared to the diabetic group (Table 3). There was a significant decrease in plasma fibronectin levels in the pioglitazone and glimepiride combination group compared to the diabetic group.

**Plasma TGF-β1**

Plasma TGF-β1 was significantly increased in the diabetic group as compared to the normal control group (Table 3). There was a significant decrease in plasma TGF-β1 content in the treated group compared to the diabetic group.

**Plasma TNF-α**

Plasma TNF-α content was significantly increased in the diabetic group as compared to the normal control group (Table 3). There was a significant decrease in plasma TNF-α in the treated group compared to the diabetic group. Additionally, more significant decrease was found in the pioglitazone and glimepiride combination treatment group compared with the rosiglitazone and glimepiride combination treatment group.

**Plasma transferrin**

Plasma transferrin content was significantly increased in the diabetic group as compared to the normal control group (Table 3). There was a significant decrease in plasma transferrin levels in the treated group compared to the diabetic group.

**DISCUSSION**

Our study demonstrated that treatment with pioglitazone and glimepiride significantly decreased fasting blood glucose and plasma insulin. The anti-diabetic activity of glimepiride is seen because it improves in-
TZD (pioglitazone and rosiglitazone) are a novel class of anti-diabetic drugs belonging to selective agonist for nuclear PPAR-γ. The antidiabetic activity of pioglitazone is seen due to the activation of genes regulating insulin sensitizing action. Pioglitazone increased insulin sensitivity in part by activating kinase of the receptors through indirect effect on insulin receptors and that the drug may have useful benefits in insulin resistance of type 2 diabetes. Diabetic rats treated with pioglitazone and glimepiride showed reduction in albumin excretion rate, total protein excretion rate, plasma fibronectin, TGF-β1, TNF-α, transferrin concentration and renal structural changes. Interventions that have ameliorated the progression of diabetic nephropathy have been associated with a reduction in urinary protein excretion, and thus renoprotective therapy should aim to achieve the maximal antialbuminuric effect. There are several mechanisms whereby increased plasma TGF-β1 has been shown to play a role in the pathogenesis of renal diseases. Thus, the reduction in plasma TGF-β1 concentration with pioglitazone and glimepiride demonstrated renoprotective effect. Pro-inflammatory cytokines such as TNF-α may play a significant role in the development of renal injury in type 2 diabetes. Therefore, results from experimental studies indicate that inhibition of TNF-α activity is associated with beneficial renal effects, suggesting that modulation of this cytokine may have a real clinical application for the treatment of DN. Reduction in plasma fibronectin and transferrin concentration with pioglitazone and glimepiride demonstrated renoprotective effect. Glimepiride and pioglitazone combination treatment showed renoprotection due to the absence of microvascular condensation and attenuation of capsular wall, capsular space and glomerular basement membrane changes. Diabetic rats treated with rosiglitazone and glimepiride showed reduction in fasting blood glucose, albumin excretion rate, total protein excretion rate, plasma insulin, TGF-β1, TNF-α, transferrin concentration and renal structural changes. Therefore, results from experimental studies indicate that rosiglitazone and
glimepiride treatment produced reduction in albumin excretion rate, total protein excretion rate, plasma TNF-α concentration and renal structural changes less than treatment with pioglitazone and glimepiride combination.

The present work compared dual therapy of rosiglitazone with glimepiride versus pioglitazone with glimepiride on STZ induced type 2 DN in rats. In conclusion, our results show that the combination of pioglitazone with glimepiride is more effective in amelioration of DN than rosiglitazone with glimepiride drug therapy due to glycemic control, suppressing albumin excretion rate, total protein excretion rate and augmenting TNF-α signaling during the development of STZ induced type 2 diabetic nephropathy.

Acknowledgements

Authors are thankful to GNCT, New Delhi, India, for financial support and Institute of Pathology-ICMR, New Delhi, India for histopathological studies. Authors also thank Panacea Biotec Ltd. Baddi, Solan (H.P.), India, for providing the gift samples of the drugs.

References

[1] Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Ind J Med Res 2007;125:217-230.
[2] Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetesologia 1983;25:496-501.
[3] Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985;78:785-794.
[4] Rossing P, Rossing K, Jacobsen P, Parving HH. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995;44:739-743.
[5] Ballard DJ, Humphrey LL, Melton LJ, Frohnhert PP, Chu PC, Ofallon WM, et al. Epidemiology of persistent proteinuria in type 2 diabetes mellitus. Population based study in Rochester, Minnesota. Diabetes 1988;37:405-412.
[6] Kunzelman CL, Knowlen WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int 1989;35:681-687.
[7] UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;12:837-853.
[8] Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
[9] Balakumar P, Chakkavarthi VA, Kumar V, Jain A, Reddy J, Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 2008;9:189-195.
[10] Hasslacher C, Ritz E, Wahl P. Similar risks of nephropathy in type 1 or type 2 diabetes mellitus. Nephrol Dial Transpl 1989;4:359-363.
[11] Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998;352:213-219.
[12] Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003;12:273-282.
[13] Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-1084.
[14] Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-296.
[15] Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, et al. Peroxisome Proliferator-Activated Receptor α/γ dual agonist Tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007;56:2036-2045.
[16] Mao Z, Ong ACM. Peroxisome Proliferator-Activated Receptor gamma agonists in kidney disease- future promise, present fears. Nephron Clin Pract 2009;112:c230-c241.
[17] Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002;25(7):1251-1252.
[18] Thomas S, Viberti G. Diabetic nephropathy. Medicine 2006;34(3):83-86.
[19] Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983;309(25):1543-1546.
[20] Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
[21] Ozata M, Kurt I, Azal O, Bolu E, Corakci A, Beyhan Z, et al. Can we use plasma fibronectin levels as a marker for early diabetic nephropathy. Endocrinol J 1995;42:301-305.
[22] Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Lenaga K, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991;40:1007-1012.
[23] Ishibashi F. Glomerular clearance and tubular reabsorption of transferrin in microtransferrinuric patients with non insulin dependent diabetes. Diabetes Res Clin Pract 1994;25:169-175.
[24] Bonner-Weir S, Trent DF, Honey RN, Weir GC. Response to neonatal islets to streptozocin, limited beta cell regeneration and hyperglycemia. Diabetes 1981;30:64-9.
[25] Sharma AK, Srivinasan BP. Triple versus glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Euro J Pharm Sci 2009;38:
[26] Blay M, Peinado-On S, Grasa MM, Diaz-silva M, Fernandez-Lopez JA, Remesar X. Effect of oral oleoyl-estrone treatment on plasma lipoproteins and tissue lipase activities of Zucker lean and obese female rats. *Int J Obesity* 2002;26(6):618-26.

[27] Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, *et al.* Acute effect of glimepiride on insulin stimulated glucose metabolism in glucose-tolerant insulin resistant offspring of patients with type 2 diabetes. *Diabetes Care* 2002;25:2065-73.

[28] Xu D, Zhao SP, Huang QX, Du W, Lin YH, Lin L, *et al.* Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. *Diabetes Res Clinical Practice* 2010;88:71-5.

[29] Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Mequro K, *et al.* Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. *Arzneim-Forsch* 1990;40:156-62.

[30] Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. *Diabetes* 1992;41(4):476-483.

[31] Border WA, Noble NA. Interaction of transforming growth factor-β and angiotensin II in renal fibrosis. *Hypertension* 1998;31:83-97.

[32] Wang SN, Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. *Am J Physiol Renal Physiol* 2000;278:F554-60.

[33] Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. *Diabetologia* 1998;41:745-59.

[34] DeJong PE, Navis GJ, DeZeeuw D. Renoprotective therapy: titration against urinary protein excretion. *Lancet* 1999;354:352-3.

[35] Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, *et al.* Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. *J Am Soc Nephrol* 2007;18:1540-6.

[36] Hasegawa G, Nakano K, Kondo M. Role of TNF-α and IL-1 in the development of diabetic nephropathy. *Nefrologia* 1995;15:1-4.

[37] Baud L, Fouqueray B, Philippe C, Amram A. Tumor necrosis factor α and mesangial cells. *Kidney Int* 1992;41:600-3.

[38] Egido J, Go mez-Chiari M, Ortiz A, Bustos C, Alonso J, *et al.* Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. *Kidney Int* 1993;43(Suppl 39):S59-64.